Skip to main content

PTSD Patients Experience Sustained Improvements After Medical Cannabis Use

International health researchers estimate that roughly 4% of the world’s total population suffers from some form of post-traumatic stress disorder (PTSD). PTSD is one of the most common mental health conditions around the globe.

PTSD is typically treated via several different therapies, with common examples including different types of trauma-focused psychotherapy as well as pharmaceutical medications. Many of the pharmaceutical medications commonly used to treat PTSD can yield undesirable side effects.

A recent study conducted in the United Kingdom examined medical cannabis therapies and PTSD, with the researchers finding that the study’s subjects experienced sustained improvements following medical cannabis use. Below is more information about the study and its results via a news release from NORML:

London, United Kingdom: Patients diagnosed with post-traumatic stress experience significant long-term benefits following their use of medical cannabis preparations, according to data published in the journal Expert Review of Neurotherapeutics.

British researchers assessed changes in patients’ health-related quality of life (HRQoL) following the use of cannabis-based medicinal products (CBMPs). (British health care providers may prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Two hundred and sixty-nine patients with post-traumatic stress enrolled in the United Kingdom’s  Medical Cannabis Registry were enrolled in the trial. Participants’ symptoms were assessed at 1, 3, 6, 12, and 18 months.

Consistent with other observational studies, “significant improvements in post-traumatic stress symptoms, anxiety, sleep quality, and HRQoL were observed at all follow-up points.” Symptomatic improvements were sustained for the entire study period (18 months).

Other observational studies assessing the use of cannabis products among patients enrolled in the UK Medical Cannabis Registry have reported them to be effective for those diagnosed with cancer-related painanxietyfibromyalgiainflammatory bowel diseasehypermobility disordersdepressionmigrainemultiple sclerosisosteoarthritis, and inflammatory arthritis, among other conditions.

Full text of the study, “UK Medical Cannabis Registry: An updated clinical outcomes analysis of patients with post-traumatic stress disorder,” appears in Expert Review of Neurotherapeutics. Additional information on cannabis and post-traumatic stress is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.

Hemp-Lime Building Blocks Could Revolutionize Construction

Humans have used the hemp plant for thousands of years, with the first evidence of human use dating back to 8,000 BCE in modern-day Taiwan, where archeologists found pottery remains containing hemp cord. Humans have also used hemp as a source for medicine since at least 2,800 BC, with the hemp plant being listed in the Chinese Emperor Shen Nung’s pharmacopoeia.

These days, hemp is still used for fiber and making various textiles, and is a source for medical products on a level never witnessed before in human history. However, hemp is also used for a wide array of other things, including bioremediation to clean up toxic sites around the world, for creating batteries, and to create the building material hempcrete.

The latter of those, hempcrete, is a bio-composite made of the inner woody core of the hemp plant mixed with a lime-based binder. The inner woody core or ‘shiv’ is high in silica content, and that allows it to naturally bind really well with lime. It is a property that is seemingly unique to hemp among all of the known natural fibers.

Currently, hempcrete is primarily used as an insulating and fill-in material. It weighs about a seventh or an eighth of the weight of concrete, floats in water when fully cured, has a negative CO2 footprint, and is nearly fireproof (at least compared to other popular building materials). One limitation of hempcrete is that it is not used as a structural element because it is not a load-bearing material.

The limitation of hemp as a source for load-bearing construction material could soon become a thing of the past, with the Cologne University of Applied Sciences reportedly having developed new hemp-lime building blocks potentially capable of being used as a material for load-bearing structures.

“These zones, like conventional hemp limestone blocks, are to be composed exclusively of biomass and mineral binders. According to the project participants, the aim is to create a climate-positive alternative to aerated concrete blocks or lightweight vertically perforated bricks, enabling single-shell masonry construction from rapidly renewable raw materials.” reported Allgemeine Bauzeitung in its local coverage (translated from German to English).

The Institute for Construction and Agricultural Machinery Technology at the Cologne University of Applied Sciences is reportedly developing a device that will be designed to produce compacted bricks made of hemp on a large scale. The resulting bricks will undergo testing to further explore their efficiency and application feasibility.

“In the second half of our project, we will devote ourselves to practical tests with our masonry blocks. We will erect several wall modules and examine their structural properties. In addition to properties such as load-bearing capacity, thermal insulation, and moisture behavior, we want to determine which materials, such as plaster and mortar, are compatible with the blocks and demonstrate that the blocks can be easily processed using conventional tools,” said project leader Prof. Dr. Arne Künstler from the Faculty of Architecture at the Cologne University of Applied Sciences according to Allgemeine Bauzeitung.

If the project’s research can prove that hemp-lime building blocks can be used as a load-bearing construction material, it would revolutionize the construction industry. Producing hemp is exponentially more sustainable compared to the production of most traditional construction materials. Cement production, for example, is a significant source of pollution around the globe.

German Scientists Call For Further Development Of Legalization

Roughly a year after Germany’s government implemented the first provisions of a national adult-use cannabis legalization measure, members of Germany’s scientific community are urging lawmakers and regulators to make further improvements to the nation’s legalization model.

“In light of the evaluation of the cannabis law announced in the coalition agreement, experts from health and legal sciences are clearly speaking out against reversing partial legalization, according to the Süddeutsche Zeitung.” the German Cannabis Business Association (BvCW) stated in a recent newsletter (translated from German to English).

“They recommend maintaining decriminalization, legally protecting cultivation clubs, and scientifically investigating the long-term effects of the law. Legalization limited to personal possession and acquisition without a legal production and distribution system makes neither health nor security policy sense.” BvCW wrote in its newsletter.

“Instead of commercialization following the North American model, they see the German model as an opportunity to research distribution through cannabis clubs—for the first time on this scale worldwide—and thus gain reliable new insights for evidence-based cannabis policy.” BvCW also stated.

Cannabis is currently legal for adult use at a national level in Uruguay, Canada, Malta, Luxembourg, Germany, and South Africa. Additionally, regional adult-use cannabis commerce pilot trials are operating in the Netherlands and Switzerland, and two dozen states in the U.S. have adopted recreational legalization.

Out of all of the legal recreational jurisdictions on the planet, none of them have the exact same legalization model. Current European Union agreements prohibit member nations from allowing robust adult-use cannabis sales like what is found in the Western Hemisphere.

However, EU agreements do permit member nations to allow adult-use cannabis activity to boost public health and research efforts. As of April 1st, 2024, adults in Germany can cultivate, possess, and consume a personal amount of cannabis. They can also join one of the nation’s licensed cultivation associations, and soon, they will be able to enroll in a regional adult-use pilot trial.

Brazilian Study Finds Cannabis Extracts Are Effective For Pediatric Autism Patients

When it comes to administering medical cannabis to pediatric patients, safety and caution are paramount. Doing so should always involve the advice, guidance, and approval of a licensed medical doctor who specializes in pediatric care.

While cases of medical cannabis being prescribed to pediatric patients are rare compared to prescriptions for non-pediatric patients, such cases do exist and rightfully so. Cannabis is medicine, as a growing list of peer-reviewed studies and individual patient cases demonstrates.

A team of researchers in Brazil recently conducted a study involving cannabis extracts and pediatric autism patients, finding that the extracts were both safe and effective. Below is more information about the study and its results via a news release from NORML:

São Paulo, Brazil: The use of cannabis extracts containing standardized percentages of CBD and THC safely mitigates autism symptoms in children, according to a systematic review of trial data published in the journal Cureus.

Brazilian researchers reviewed findings from seven studies (three randomized clinical trials and four observational studies) involving 494 younger patients with autism spectrum disorder. Study participants consumed extracts dominant in cannabidiol.

Researchers reported, “CBD-rich formulations may hold promise for managing certain ASD symptoms. Improvements were noted in anxiety, sleep quality, social effects, and behavior, although these findings varied across studies. Importantly, adverse events were generally mild and occurred at similar rates in cannabinoid and placebo groups, supporting the intervention’s safety profile.”

The study’s authors concluded, “More rigorous, well-designed RCTs [randomized controlled trials] are necessary to confirm these results and establish clear treatment guidelines for cannabinoid use in ASD.”

Full text of the study, “Efficacy and safety of cannabinoids for autism spectrum disorder: An updated systematic review,” appears in Cureus. Additional information on cannabinoids and ASD is available from NORML’s publication, Clinical Applications for Cannabis and Cannabinoids.

Poland Study Finds Cannabinoid Ointment Relieves Eczema Symptoms

Eczema is a common skin condition that causes dry, itchy, and inflamed skin in people who suffer from it. Eczema is also known as atopic dermatitis. Researchers estimate that roughly 10% to 20% of children and 2% to 10% of adults worldwide have eczema.

Common treatments for eczema include over-the-counter products that may help to some degree. Pharmaceutical drugs are also sometimes prescribed for eczema sufferers, including non-steroid topical creams, steroid topical creams, and daily pill prescriptions.

A team of researchers in Poland recently conducted a study examining the application of cannabinoid-based ointments and eczema. Below is more information about the study and its findings via a news release from NORML:

Katowice, Poland: The topical administration of an ointment containing standardized percentages of CBD and CBG (cannabigerol) mitigates symptoms and improves the health-related quality of life in patients with atopic dermatitis (eczema), according to observational data published in the journal Clinical, Cosmetic and Investigational Dermatology.

Polish investigators assessed the transdermal use of cannabinoids in nine patients diagnosed with AD. Study participants applied a cannabinoid-infused ointment containing 30 percent CBD and five percent CBG daily for eight weeks.

Cannabis treatment led to the remission of skin lesions and other changes in skin parameters, including improved hydration and less itching.

“Our results demonstrate that topical cannabinoid therapy is effective in reducing itching and improving the quality of life of patients with AD, leading to symptom remission in some cases,” the study’s authors concluded.

The results are consistent with those of prior studies finding that the topical application of cannabinoids provides benefits in treating various skin-related conditions, including psoriasiserythemapruritus, and acne. Cannabinoid treatment is also associated with wound healing in patients with refractory leg ulcers and has demonstrated positive results in patients suffering from the skin blistering disease epidermolysis bullosa.

Full text of the study, “Evaluation of biophysical parameters of the skin of patients with atopic dermatitis after application of an ointment containing 30% cannabidiol and 5% cannabigerol,” appears in Clinical, Cosmetic and Investigational Dermatology.

Vaporized Cannabis Provides “Significant Improvements” For MS Patients

Cannabis consumption has evolved in recent decades. For many years, cannabis was typically eaten or it was combusted with a flame, and the resulting smoke was inhaled. These days, cannabis is vaporized by more and more medical cannabis patients for various reasons.

According to SNS Insider, the cannabis vape market “was valued at USD 5.06 billion in 2023 and is expected to grow to USD 17.11 billion by 2032, at a CAGR of 14.53% over the forecast period of 2024-2032.”

Researchers in Greece recently conducted a study involving vaporized medical cannabis and multiple sclerosis patients. Below is more information about the study and its results via a news release from NORML:

Athens, Greece: Vaporized cannabis containing standardized percentages of CBD and THC is associated with sustained improvements in patients with multiple sclerosis (MS), according to longitudinal data published in the Journal of Clinical Medicine.

Greek researchers assessed the efficacy of a vaporized cannabis formulation containing 13 percent CBD and 9 percent THC in a cohort of 69 MS patients. Study participants’ symptoms – including bladder dysfunction, muscle spasticity, and disability progression rate – were assessed at baseline, at three months, and six months.

“Significant improvement was observed across all outcome assessments” following patients’ adjunctive use of cannabis, researchers reported.

“This study represents an initial step toward understanding the real-world application of vaporized THC: CBD formulations in MS management,” the study’s authors concluded. “The findings … highlight the potential benefits of CBD 13 [percent] | THC 9 [percent] vaporized formulations in managing MS symptoms, particularly when integrated into the existing treatment framework of DMTs [disease modifying therapies] and other MS symptomatic therapies.”

In 2010, British health officials granted regulatory approval to an oromucosal spray (nabiximols) containing standardized percentages of CBD and THC for the treatment of MS. That product is now available by prescription in various countries – including Canada, Germany, Israel, Japan, and Spain – but remains unavailable in the United States.

Full text of the study, “Evaluating vaporized cannabinoid therapy in multiple sclerosis: Findings from a prospective single-center clinical study,” appears in the Journal of Clinical MedicineAdditional information on cannabis and MS is available from NORML’s publication, Clinical Applications for Cannabis and Cannabinoids.

Medical Cannabis Associated With “Meaningful Improvements” In Patients’ Quality of Life

Nearly five dozen nations now permit some form of legal access to medical cannabis. Tens of thousands of peer-reviewed studies have focused on the medical benefits of cannabis, finding that it is an effective form of medicine. Legal medical cannabis is big business, too.

According to Persistence Market Research, “the global medical marijuana market is expected to grow from USD 33.1 Bn in 2025 to USD 83.1 Bn by 2032, registering a CAGR of 14.0% during the forecast period.”

A team of health researchers in Australia recently conducted a study examining medical cannabis’ impact on the health-related quality of life of patients who use it. Below is more information about the study via a news release from NORML:

Sydney, Australia: The use of physician-authorized medical cannabis products is associated with “statistically significant and clinically meaningful improvements” in patients’ health, according to observational study data published in the journal PLOS One.

Researchers assessed the efficacy of cannabis oil extracts containing standardized ratios of THC and CBD in more than 2,000 patients over one year. (Under Australian law, physicians may authorize cannabis products to patients unresponsive to conventional prescription treatments.)

Consistent with prior studies, patients reported sustained improvements following cannabis therapy.

“Statistically significant and clinically meaningful improvements were observed in HRQL [health-related quality of life], fatigue, pain, and sleep for people with chronic health conditions,” investigators concluded. “Similar improvements were found in pain outcomes for participants with chronic pain; sleep disturbance for participants with insomnia; depression scores for patients with depression; and anxiety scores in patients with anxiety. … The findings from this study contribute to the emerging evidence-base to inform decision making both in clinical practice and at policy level.”

Similarly designed studies involving patients enrolled in the United Kingdom’s medical marijuana access program have shown cannabis products to be safe and effective for those suffering from cancer-related painanxietyfibromyalgiainflammatory bowel diseasepost-traumatic stressdepressionmigrainemultiple sclerosisosteoarthritishypermobility disorders, and inflammatory arthritis, among other conditions.

Full text of the study, “Improvements in health-related quality of life are maintained long-term in patients prescribed medicinal cannabis in Australia: The QUEST Initiative 12-month follow up observational study,” appears in PLOS One. Additional information about the therapeutic use of cannabis is available from NORML’s publication, Clinical Application for Cannabis and Cannabinoids.

Another Historic International Cannabis Business Conference In Barcelona

The International Cannabis Business Conference, Spain’s largest cannabis B2B event, was held at the iconic L’Auditori de Cornellà in Barcelona, Spain, on March 13th, 2025. The International Cannabis Business Conference again partnered with Spannabis to put on another historic cannabis super-conference.

For the last decade, the International Cannabis Business Conference event series has served as the world’s premiere destination for industry networking, policy education, and entertainment.

Barcelona’s rich cannabis history and culture made it the perfect backdrop for the event. The conference also occurred when lawmakers and regulators are closer than ever to adopting a modernized medical cannabis industry regulatory system. Spain’s emerging industry is one of the largest on the planet, however, much remains unregulated.

Domestic medical cannabis production is permitted in Spain but is geared toward supplying research projects and international exports. A modernized framework is needed to boost safe access for Spain’s patients and provide greater certainty for entrepreneurs and investors.

Dozens of world-class experts provided presentations and panel discussions covering a wide range of important topics at the International Cannabis Business Conference in Barcelona, including:

  • International business development and strategy
  • Seed to sale operations
  • Branding and marketing
  • Capital raising
  • Cross-border IP licensing
  • Mergers and acquisitions
  • Non-psychative cannabinoids
  • European medical cannabis supply chain
  • Impacts of German cannabis policy modernization
  • Lessons learned from a decade of Uruguay legalization
  • Cannabis genetics
  • Industrial hemp
  • European Union cannabis data
  • Emerging cannabis cultivation technology
  • Forming strategic partnerships

Spain’s cannabis industry is estimated to be worth 358.4 million euros, according to an analysis by Euromonitor International.

Spannabis previously teamed up with the International Cannabis Business Conference to host past super-conferences, and the collaborations were a tremendous success. The 2025 cannabis super-conference was the largest and most exciting collaboration to date.

Improved Mental Health Reported In Swiss Cannabis Study

Switzerland is home to a somewhat unique set of cannabis commerce public policy experiments. The research experiments are known as regional adult-use cannabis commerce ‘pilot trials’ and involve permitting legal sales at a local level to help government officials gather data.

Multiple markets have trials operating in Switzerland, including in Basel, where recently examined data found that pilot trial participants report ‘improved mental health’ after consuming legal recreational cannabis products.

“Over the course of the two-year “Weedcare” recreational cannabis study, depressive symptoms and anxiety decreased among the participants, Basel City’s Department of Health reported on Friday. They also showed less addictive behaviour.” Swiss Info stated in its local coverage.

“The study is being led by Basel City’s Department of Health, together with the University Psychiatric Clinics Basel, the Psychiatric Services Aargau and the University of Basel.” the outlet also reported.

Basel’s pilot trial was the first to launch in Switzerland. In addition to Switzerland’s research trials, cannabis pilot trials are also operating in multiple jurisdictions in the Netherlands and are expected to launch soon in Germany.

In the first two years of Basel’s study, which involves a reported 300 participants, 87 kilograms of cannabis products were sold. The pilot trial in Basel is slated to continue until January 2027, at which point government officials will publish a final report.